Journal of Blood & Lymph

Objective:
In our study we analysed thromboembolic (TE) events of ET patients using data from the Hungarian Myeloproliferative Neoplasm (HUMYPRON) registry. We examined possible thrombosis risk factors and compared Landolfi-, IPSET- and R-IPSET risk stratification models.

Methods:
The HUMYPRON registry was established in 2012 and contains data of patients from 14 Hungarian haematology centres. We analysed clinical and laboratory data of 237 ET (according to 2008 WHO classification) patients to assess possible risk factors of post-diagnostic TE events and to study the applicability of Landolfi-, IPSET- and R-IPSET thrombosis risk stratifications. 

Results:
237 ET patients were followed for median 10 years. After diagnosis 76 patients (32.1%) had TE complication. Previous thrombotic episode was found to be the only factor that had significant effect on TE events after diagnosis (p<0.001). On our sample R-IPSET proved to be the strongest model, where the frequency of TE events was 14.3% in the very low and 46% in the high risk patient group. 

Conclusions:
During the follow-up period of median 10 years, prior TE event was the only factor that had highly significant effect on post-diagnostic thrombosis. Among the risk stratification systems R-IPSET model proved to be the strongest.

Keywords:
Essential Thrombocythemia | Thrombosis | Humypron Registry | Risk Factors | Thrombosis Risk Models

Congestive vascular failure develops when ventricles unable to pump enough volume of blood to the body. Increase in the prevalence of cardiovascular diseases across regions is the major factors expected to drive the revenue growth of congestive vascular failure treatment globally. Lifestyle-related factors are expected to add to the growing disease incidence of CVDs. In addition, the growing number of obese patients is expected to bolster the congestive heart failure treatment market. The huge treatment demand for congestive vascular failure is expected to boost the treatment market. However, the availability of the generic drugs and lack of end-stage pipeline drugs and therapies for congestive vascular failure treatment is about to hinder the market.

The 5th Annual Meet on Structural Biology is slated to take place during August 24-25, 2020 at Dublin, Ireland which objects on foremost topics such as Structural biology , Systems Biology, Structural and Cell Biology, Bio-Engineering, Bio Physics and Structural Biology Immunology, Nano Engineering ,Stem cell biology and Regenerative medicine, Cancer Biology The past International conferences on Cell and Structural Biology strenuous on diverse areas related to Science and their extensive applications which have engaged protruding speakers which embraces eminent scientists from premium International Universities and experts from distinguished associations. Formerly organized conference can be seen in conference series webpage.

The pharmaceutical industry plays a significant role in developing medications and vaccines to reduce the incidence of diseases, to treat diseases and enhance the quality of life of people. The industry’s main contribution is engaging in technological advancements through innovative research to meet the complex healthcare demands of populations. The global market for pharmaceuticals is expected to grow at an annual rate of 4.9% to $1.3 trillion by 2020. The U.S pharma market is expected to grow to $320 billion by 2020. The Japan market, the third largest pharmaceutical market, has a forecasted growth of 3% while the U.S has an expected growth rate of 5.6%.

Hypertension Congress 2020 is a rare venue to bring together prominent scholars from around the world in the fields of cardiology, nephropathy, neuropathy, endocrinology, psychology, public health practitioners, scientists, educational scientists, and industry experts, educators to share views on state-of - the-art studies and provide the best opportunity to reach the largest gathering of participants.